BioNTech's (BNTX) Buy Rating Reaffirmed at Jefferies Financial Group

Key Points

• Jefferies Financial Group reiterated a Buy rating on BioNTech in a recent research note.
• Analyst consensus counts 13 Buys, 4 Holds and 1 Sell, giving a "Moderate Buy" average and a consensus target price of $133.73.
• Shares opened around $88.64, well below the consensus target, with a market cap of $21.27 billion, a negative P/E (-16.93), and 50-/200-day SMAs near $104.95 and $101.91.

BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Jefferies Financial Group in a research note issued on Wednesday,MarketScreener reports.

BNTX has been the subject of several other research reports. BMO Capital Markets lowered their target price on shares of BioNTech from $143.00 to $128.00 and set an "outperform" rating for the company in a research note on Wednesday, March 11th. Citigroup lowered their price objective on shares of BioNTech from $145.00 to $130.00 and set a "buy" rating for the company in a research report on Wednesday, March 11th. UBS Group raised BioNTech to a "hold" rating in a research report on Thursday, December 4th. TD Cowen lowered their price target on BioNTech from $116.00 to $94.00 and set a "hold" rating for the company in a research report on Wednesday, March 11th. Finally, Leerink Partners cut BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 price objective for the company. in a research note on Monday, February 2nd. Thirteen investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and a consensus target price of $133.73.

BioNTech Stock Performance

NASDAQ BNTX opened at $88.64 on Wednesday. The stock has a fifty day simple moving average of $104.95 and a 200-day simple moving average of $101.91. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01. The stock has a market cap of $21.27 billion, a PE ratio of -16.93 and a beta of 1.51. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC purchased a new stake in shares of BioNTech during the 4th quarter worth $4,969,000. Rockefeller Capital Management L.P. raised its stake in BioNTech by 328.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company's stock valued at $177,000 after buying an additional 1,423 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company's stock worth $53,000 after buying an additional 506 shares during the last quarter. Sankala Group LLC acquired a new position in shares of BioNTech during the 4th quarter worth about $248,000. Finally, Virtu Financial LLC increased its holdings in shares of BioNTech by 163.9% in the 4th quarter. Virtu Financial LLC now owns 11,244 shares of the company's stock valued at $1,070,000 after acquiring an additional 6,984 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.